WO2000027994A3 - Chlamydia pneumoniae genome sequence - Google Patents
Chlamydia pneumoniae genome sequence Download PDFInfo
- Publication number
- WO2000027994A3 WO2000027994A3 PCT/US1999/026923 US9926923W WO0027994A3 WO 2000027994 A3 WO2000027994 A3 WO 2000027994A3 US 9926923 W US9926923 W US 9926923W WO 0027994 A3 WO0027994 A3 WO 0027994A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- genome sequence
- expression
- pneumoniae genome
- chlamydia pneumoniae
- pneumoniae
- Prior art date
Links
- 241001647372 Chlamydia pneumoniae Species 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99960323A EP1133572A4 (en) | 1998-11-12 | 1999-11-12 | Chlamydia pneumoniae genome sequence |
CA002350775A CA2350775A1 (en) | 1998-11-12 | 1999-11-12 | Chlamydia pneumoniae genome sequence |
AU17223/00A AU1722300A (en) | 1998-11-12 | 1999-11-12 | Chlamydia pneumoniae genome sequence |
JP2000581161A JP2002529069A (en) | 1998-11-12 | 1999-11-12 | Chlamydia pneumoniae genome sequence |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10827998P | 1998-11-12 | 1998-11-12 | |
US60/108,279 | 1998-11-12 | ||
US12860699P | 1999-04-08 | 1999-04-08 | |
US60/128,606 | 1999-04-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000027994A2 WO2000027994A2 (en) | 2000-05-18 |
WO2000027994A3 true WO2000027994A3 (en) | 2000-11-23 |
Family
ID=26805735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/026923 WO2000027994A2 (en) | 1998-11-12 | 1999-11-12 | Chlamydia pneumoniae genome sequence |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1133572A4 (en) |
JP (1) | JP2002529069A (en) |
AU (1) | AU1722300A (en) |
CA (1) | CA2350775A1 (en) |
WO (1) | WO2000027994A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108514870A (en) * | 2018-04-27 | 2018-09-11 | 湖南大学 | Hydrotalcite-poly m-phenylene diamine composite material and preparation method and application |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2283012T3 (en) | 1996-01-04 | 2007-10-16 | Novartis Vaccines And Diagnostics, Inc. | HELICOBACTER PYLORI BACTERIOFERRITINE. |
US6686339B1 (en) | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
CA2340330A1 (en) | 1998-08-20 | 2000-03-02 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein c of chlamydia |
WO2000011180A1 (en) | 1998-08-20 | 2000-03-02 | Connaught Laboratories Limited | NUCLEIC ACID MOLECULES ENCODING POMP91A PROTEIN OF $i(CHLAMYDIA) |
US6649370B1 (en) | 1998-10-28 | 2003-11-18 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US6607730B1 (en) | 1998-11-02 | 2003-08-19 | Aventis Pasteur Limited/Aventis Pasteur Limitee | Chlamydia antigens and corresponding DNA fragments and uses thereof |
JP2002531093A (en) | 1998-12-01 | 2002-09-24 | アベンティス、パストゥール、リミテッド | Chlamydia antigens and corresponding DNA fragments and uses thereof |
EP1144642B1 (en) | 1998-12-08 | 2010-05-26 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
US20020061848A1 (en) | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
EP1140999A1 (en) | 1998-12-23 | 2001-10-10 | Aventis Pasteur Limited | $i(CHLAMYDIA) ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF |
US7297341B1 (en) | 1998-12-23 | 2007-11-20 | Sanofi Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US6808713B1 (en) | 1998-12-28 | 2004-10-26 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
DE69938059T2 (en) | 1998-12-28 | 2009-01-08 | Sanofi Pasteur Ltd., Toronto | CHLAMYDIA ANTIGENE, CORRESPONDING DNA FRAGMENTS AND ITS USES |
GB9902555D0 (en) | 1999-02-05 | 1999-03-24 | Neutec Pharma Plc | Medicament |
EP1163342B1 (en) | 1999-03-12 | 2008-12-10 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
CA2370441A1 (en) * | 1999-03-26 | 2000-10-05 | Craig A. Rosen | 50 human secreted proteins |
CA2368374A1 (en) * | 1999-03-26 | 2000-10-05 | Human Genome Sciences, Inc. | 47 human secreted proteins |
WO2000066739A2 (en) | 1999-05-03 | 2000-11-09 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
NZ517952A (en) | 1999-09-20 | 2004-01-30 | Aventis Pasteur | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
NZ520200A (en) | 1999-12-22 | 2004-04-30 | Aventis Pasteur | Polynucleotides encoding the Clamydia pneumoniae polypeptides omp P6 precursor gene product |
EP1278855B1 (en) | 2000-04-21 | 2008-03-12 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
EP1282718B1 (en) | 2000-05-08 | 2006-12-20 | Sanofi Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
ATE440861T1 (en) | 2000-07-03 | 2009-09-15 | Novartis Vaccines & Diagnostic | IMMUNIZATION AGAINST CHLAMYDIA PNEUMONIAE |
US7537772B1 (en) | 2000-10-02 | 2009-05-26 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, gene sequence and the uses thereof |
US7731980B2 (en) | 2000-10-02 | 2010-06-08 | Emergent Product Development Gaithersburg Inc. | Chlamydia PMP proteins, gene sequences and uses thereof |
MXPA03003690A (en) | 2000-10-27 | 2004-05-05 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a b. |
US20030059896A1 (en) * | 2000-12-21 | 2003-03-27 | Shire Biochem Inc. | Novel chlamydia antigens and corresponding DNA fragments |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
NZ562929A (en) | 2001-12-12 | 2009-07-31 | Novartis Vaccines & Diagnostic | Immunisation against chlamydia trachomatis |
GB0203403D0 (en) | 2002-02-13 | 2002-04-03 | Chiron Spa | Chlamydia cytotoxic-T cell epitopes |
EP2572707A3 (en) | 2002-02-20 | 2013-11-06 | Novartis Vaccines and Diagnostics, Inc. | Microparticles with adsorbed polypeptide-containing molecules |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
DK2395073T3 (en) | 2002-11-01 | 2017-10-23 | Glaxosmithkline Biologicals Sa | Process for drying. |
US20070059329A1 (en) | 2002-11-15 | 2007-03-15 | Nathalie Norais | Unexpected surface proteins in meningococcus |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
EP2258365B1 (en) | 2003-03-28 | 2013-05-29 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
WO2005020964A1 (en) | 2003-06-02 | 2005-03-10 | Chiron Corporation | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
EP1768662A2 (en) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
JP2008504292A (en) | 2004-06-24 | 2008-02-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | Immune enhancement compounds |
EP1784211A4 (en) | 2004-07-29 | 2010-06-30 | Novartis Vaccines & Diagnostic | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
CN101203529A (en) | 2005-02-18 | 2008-06-18 | 诺华疫苗和诊断公司 | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
SG160329A1 (en) | 2005-02-18 | 2010-04-29 | Novartis Vaccines & Diagnostic | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
JP2009511636A (en) | 2005-10-18 | 2009-03-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | Mucosal and systemic immunity with alphavirus replicon particles |
JP5215865B2 (en) | 2005-11-22 | 2013-06-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | Norovirus and sapovirus antigens |
CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
EP2064230A2 (en) | 2006-08-16 | 2009-06-03 | Novartis AG | Immunogens from uropathogenic escherichia coli |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
RU2471497C2 (en) | 2007-09-12 | 2013-01-10 | Новартис Аг | Mutant antigens gas57 and gas57 antibodies |
WO2009081274A2 (en) | 2007-12-21 | 2009-07-02 | Novartis Ag | Mutant forms of streptolysin o |
DK2349520T3 (en) | 2008-10-27 | 2016-08-15 | Glaxosmithkline Biologicals Sa | Purification Procedure for Group A Streptococcus Carbohydrate |
CA2781805A1 (en) * | 2008-12-17 | 2010-07-08 | Genocea Biosciences, Inc. | Chlamydia antigens and uses thereof |
BRPI1005670A8 (en) | 2009-01-05 | 2017-12-26 | Epitogenesis Inc | adjuvant compositions and processes of use. |
CA2749367A1 (en) | 2009-01-12 | 2010-07-15 | Novartis Ag | Cna_b domain antigens in vaccines against gram positive bacteria |
US8568732B2 (en) | 2009-03-06 | 2013-10-29 | Novartis Ag | Chlamydia antigens |
AU2010352695B2 (en) | 2009-09-30 | 2014-08-21 | Glaxosmithkline Biologicals S.A. | Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides |
EP3199177A1 (en) | 2009-10-30 | 2017-08-02 | GlaxoSmithKline Biologicals S.A. | Purification of staphylococcus aureus type 5 and type 8 capsular saccharides |
CN102933267B (en) | 2010-05-28 | 2015-05-27 | 泰特里斯在线公司 | Interactive hybrid asynchronous computer game infrastructure |
GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
US20120135025A1 (en) * | 2010-10-20 | 2012-05-31 | Genocea Biosciences, Inc. | Chlamydia antigens and uses thereof |
EP2655389A2 (en) | 2010-12-24 | 2013-10-30 | Novartis AG | Compounds |
CN103717235A (en) | 2011-06-24 | 2014-04-09 | 埃皮托吉尼西斯有限公司 | Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
CN103917245B (en) | 2011-09-14 | 2017-06-06 | 葛兰素史密丝克莱恩生物有限公司 | Method for preparing glycoprotein glycoconjugate |
CA2854934A1 (en) | 2011-11-07 | 2013-05-16 | Novartis Ag | Carrier molecule comprising a spr0096 and a spr2021 antigen |
MX2014014067A (en) | 2012-05-22 | 2015-02-04 | Novartis Ag | Meningococcus serogroup x conjugate. |
BE1024634B1 (en) | 2016-04-05 | 2018-05-14 | Gsk Vaccines S.R.L. | IMMUNOGENIC COMPOSITIONS |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5374718A (en) * | 1992-08-26 | 1994-12-20 | Gen-Probe Incorporated | Nucleic acid probes to chlamydia pneumoniae |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08294400A (en) * | 1995-04-28 | 1996-11-12 | Hitachi Chem Co Ltd | Probe and primer for detecting and measuring chlamydia pneumoniae gene, detection and measurement of chlamydia pneumoniae gene using the same probe or primer and reagent for detecting and measuring chlamydia pneumoniae gene containing the same probe or primer |
JPH10210978A (en) * | 1997-01-31 | 1998-08-11 | Hitachi Chem Co Ltd | Recombinant vector and transformant containing the same, and recombinant vacurovirus and its production, and production of chlamydia pneumoniae antigen polypeptide |
-
1999
- 1999-11-12 JP JP2000581161A patent/JP2002529069A/en not_active Withdrawn
- 1999-11-12 EP EP99960323A patent/EP1133572A4/en not_active Withdrawn
- 1999-11-12 AU AU17223/00A patent/AU1722300A/en not_active Abandoned
- 1999-11-12 CA CA002350775A patent/CA2350775A1/en not_active Abandoned
- 1999-11-12 WO PCT/US1999/026923 patent/WO2000027994A2/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5374718A (en) * | 1992-08-26 | 1994-12-20 | Gen-Probe Incorporated | Nucleic acid probes to chlamydia pneumoniae |
US5683870A (en) * | 1992-08-26 | 1997-11-04 | Gen-Probe Incorporated | Nucleic acid probes to Chlamydia pneumoniae |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108514870A (en) * | 2018-04-27 | 2018-09-11 | 湖南大学 | Hydrotalcite-poly m-phenylene diamine composite material and preparation method and application |
CN108514870B (en) * | 2018-04-27 | 2020-02-28 | 湖南大学 | Hydrotalcite-poly (m-phenylenediamine) composite material and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2002529069A (en) | 2002-09-10 |
EP1133572A4 (en) | 2005-06-15 |
EP1133572A2 (en) | 2001-09-19 |
AU1722300A (en) | 2000-05-29 |
CA2350775A1 (en) | 2000-05-18 |
WO2000027994A2 (en) | 2000-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000027994A3 (en) | Chlamydia pneumoniae genome sequence | |
WO2002014358A3 (en) | Novel secreted proteins and their uses | |
EP1005540A4 (en) | Ikk-beta proteins, nucleic acids and methods | |
WO2002029086A3 (en) | Nucleic acid sequences differentially expressed in cancer tissue | |
EP0804609A4 (en) | NOVEL p53 RESPONSE GENES | |
CA2281895A1 (en) | Ikb kinases | |
WO2000008157A3 (en) | Human anion transporter genes atnov | |
WO1998011234A3 (en) | Human protein kinases | |
WO1999054447A3 (en) | Human nucleic acid sequences of bladder tumour tissue | |
WO1998018822A3 (en) | Novel human lim proteins | |
WO2002032939A3 (en) | Secreted proteins and their uses | |
AU2001238064A1 (en) | 18477, a human protein kinase and uses therefor | |
WO2002034922A3 (en) | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | |
WO2002026801A3 (en) | Secreted proteins and their uses | |
WO2002048361A3 (en) | Novel secreted proteins and their uses | |
WO2002016578A3 (en) | Secreted proteins and methods of using same | |
MXPA01004353A (en) | Chlamydia. | |
WO2000058464A3 (en) | Rab genes and their uses | |
WO2002012475A3 (en) | C1q-related factor, homologous polypeptides and therapeutic uses thereof | |
WO2001036478A3 (en) | Methods and compositions relating to bactericidal/permeability increasing factor-like polypeptides and polynucleotides | |
WO2002064827A3 (en) | Nucleic acids of the human abca12 gene, vectors containing such nucleic acids, and uses thereof | |
EP1383871A4 (en) | Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof | |
EP1383877A4 (en) | Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof | |
EP1383908A4 (en) | Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof | |
WO2005049818A3 (en) | Genes encoding human deubiquitinating enzymes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 17223 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2350775 Country of ref document: CA Ref country code: CA Ref document number: 2350775 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 581161 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999960323 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999960323 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999960323 Country of ref document: EP |